Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Stem Cell Pathology.

Fu DJ, Miller AD, Southard TL, Flesken-Nikitin A, Ellenson LH, Nikitin AY.

Annu Rev Pathol. 2018 Jan 24;13:71-92. doi: 10.1146/annurev-pathol-020117-043935. Epub 2017 Oct 20. Review.

2.

LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.

Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.

Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.

3.

Transplantation Into the Mouse Ovarian Fat Pad.

Flesken-Nikitin A, Harlan BA, Nikitin AY.

J Vis Exp. 2016 Sep 7;(115). doi: 10.3791/54444.

4.

Role of the stem cell niche in the pathogenesis of epithelial ovarian cancers.

Flesken-Nikitin A, Odai-Afotey AA, Nikitin AY.

Mol Cell Oncol. 2014 Oct 31;1(3):e963435. doi: 10.4161/23723548.2014.963435. eCollection 2014 Jul-Sep. Review.

5.

miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment.

Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Öner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY.

Cell Rep. 2014 Mar 27;6(6):1000-1007. doi: 10.1016/j.celrep.2014.02.023. Epub 2014 Mar 13. Erratum in: Cell Rep. 2015 Sep 29;12(12):2181.

6.

Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche.

Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY.

Nature. 2013 Mar 14;495(7440):241-5. doi: 10.1038/nature11979. Epub 2013 Mar 6.

7.

MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, Nikitin AY.

Cell Cycle. 2011 Nov 15;10(22):3834-40. doi: 10.4161/cc.10.22.18294. Epub 2011 Nov 15.

8.

Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. doi: 10.1073/pnas.1017536108. Epub 2011 Aug 9.

9.

Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.

Choi J, Curtis SJ, Roy DM, Flesken-Nikitin A, Nikitin AY.

Am J Pathol. 2010 Nov;177(5):2645-58. doi: 10.2353/ajpath.2010.100306. Epub 2010 Sep 23.

10.

Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.

Cheng L, Zhou Z, Flesken-Nikitin A, Toshkov IA, Wang W, Camps J, Ried T, Nikitin AY.

Oncogene. 2010 Oct 21;29(42):5700-11. doi: 10.1038/onc.2010.300. Epub 2010 Aug 2.

11.

Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.

Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, Nikitin AY, Roy-Burman P.

Horm Cancer. 2010 Feb;1(1):44-54. doi: 10.1007/s12672-009-0005-y.

12.

Conditional knockout of fibronectin abrogates mouse mammary gland lobuloalveolar differentiation.

Liu K, Cheng L, Flesken-Nikitin A, Huang L, Nikitin AY, Pauli BU.

Dev Biol. 2010 Oct 1;346(1):11-24. doi: 10.1016/j.ydbio.2010.07.001. Epub 2010 Aug 10.

13.

Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy.

Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, Zipfel WR.

Transl Oncol. 2010 Jun 1;3(3):181-94.

14.

Frequent downregulation of miR-34 family in human ovarian cancers.

Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY.

Clin Cancer Res. 2010 Feb 15;16(4):1119-28. doi: 10.1158/1078-0432.CCR-09-2642. Epub 2010 Feb 9.

15.

Mouse models for cancer stem cell research.

Cheng L, Ramesh AV, Flesken-Nikitin A, Choi J, Nikitin AY.

Toxicol Pathol. 2010 Jan;38(1):62-71. doi: 10.1177/0192623309354109. Epub 2009 Nov 17. Review.

16.

Role of p53 and Rb in ovarian cancer.

Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY.

Adv Exp Med Biol. 2008;622:99-117. doi: 10.1007/978-0-387-68969-2_9. Review. No abstract available.

17.

Core-shell silica nanoparticles as fluorescent labels for nanomedicine.

Choi J, Burns AA, Williams RM, Zhou Z, Flesken-Nikitin A, Zipfel WR, Wiesner U, Nikitin AY.

J Biomed Opt. 2007 Nov-Dec;12(6):064007. doi: 10.1117/1.2823149.

18.

Toxicity and biomedical imaging of layered nanohybrids in the mouse.

Flesken-Nikitin A, Toshkov I, Naskar J, Tyner KM, Williams RM, Zipfel WR, Giannelis EP, Nikitin AY.

Toxicol Pathol. 2007 Oct;35(6):806-12.

PMID:
17943654
19.

Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia.

Matoso A, Zhou Z, Hayama R, Flesken-Nikitin A, Nikitin AY.

Carcinogenesis. 2008 Mar;29(3):620-8. Epub 2007 Sep 24.

PMID:
17893233
20.

MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.

Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY.

Cancer Res. 2007 Sep 15;67(18):8433-8. Epub 2007 Sep 6.

21.

Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts.

Zhou Z, Flesken-Nikitin A, Nikitin AY.

Cancer Res. 2007 Jun 15;67(12):5683-90. Epub 2007 Jun 6.

22.

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY.

Cancer Res. 2006 Aug 15;66(16):7889-98.

23.

Suppression of melanotroph carcinogenesis leads to accelerated progression of pituitary anterior lobe tumors and medullary thyroid carcinomas in Rb+/- mice.

Zhou Z, Flesken-Nikitin A, Levine CG, Shmidt EN, Eng JP, Nikitina EY, Spencer DM, Nikitin AY.

Cancer Res. 2005 Feb 1;65(3):787-96.

24.

Use of multiphoton imaging for studying cell migration in the mouse.

Flesken-Nikitin A, Williams RM, Zipfel WR, Webb WW, Nikitin AY.

Methods Mol Biol. 2005;294:335-45.

PMID:
15576922
25.

Mammary carcinoma suppression by cellular retinoic acid binding protein-II.

Manor D, Shmidt EN, Budhu A, Flesken-Nikitin A, Zgola M, Page R, Nikitin AY, Noy N.

Cancer Res. 2003 Aug 1;63(15):4426-33.

26.

Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY.

Cancer Res. 2003 Jul 1;63(13):3459-63.

27.

Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice.

Sharp ZD, Lee WH, Nikitin AY, Flesken-Nikitin A, Ikeno Y, Reddick R, Richardson AG, Nelson JF.

Carcinogenesis. 2003 Feb;24(2):179-83.

PMID:
12584165
28.

Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.

Nikitin AY, Liu CY, Flesken-Nikitin A, Chen CF, Chen PL, Lee WH.

Cancer Res. 2002 Sep 15;62(18):5134-8.

29.

Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability.

Zheng L, Flesken-Nikitin A, Chen PL, Lee WH.

Cancer Res. 2002 May 1;62(9):2498-502.

30.

The retinoblastoma gene regulates somatic growth during mouse development.

Nikitin AYu, Shan B, Flesken-Nikitin A, Chang KH, Lee WH.

Cancer Res. 2001 Apr 1;61(7):3110-8.

31.

Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.

Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH.

Mol Cell. 2000 Oct;6(4):757-68.

32.
33.

Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells.

Nikitin AY, Jin JJ, Papewalis J, Prokopenko SN, Pozharisski KM, Winterhager E, Flesken-Nikitin A, Rajewsky MF.

Oncogene. 1996 Mar 21;12(6):1309-17.

PMID:
8649833

Supplemental Content

Loading ...
Support Center